LUCD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.39M

+15.94%

-0.102

-48.4%

1.55M

+86.59%

-0.095

-81.73%

2.00M

+71.69%

-0.083

+3.13%

Estimates Revision

The market is revising No Change the revenue expectations for Lucid Diagnostics Inc. (LUCD) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 2.61%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+2.61%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast LUCD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LUCD is 3.75 USD with a low forecast of 2.50 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

2.50

Averages

3.75

High

8.00

Current: 0.000

Low

2.50

Averages

3.75

High

8.00

Ascendiant

Edward Woo

Buy

maintain

2025-12-10

Reason

Ascendiant

Edward Woo

Price Target

2025-12-10

maintain

Buy

Reason

Ascendiant analyst Edward Woo raised the firm's price target on Lucid Diagnostics to $8.25 from $8 and keeps a Buy rating on the shares following the company's Q3 report issued on November 12. Expected high growth and Medicare coverage in 2026 should drive the stock "much higher," the analyst contends.

BTIG

Mark Massaro

Buy

maintain

2025-09-05

Reason

BTIG

Mark Massaro

Price Target

2025-09-05

maintain

Buy

Reason

BTIG analyst Mark Massaro raised the firm's price target on Lucid Diagnostics to $2.50 from $2 and keeps a Buy rating on the shares. Attending the CMS meeting to discuss the merits of Medicare coverage for Lucid's EsoGuard test, the firm heard "unanimously positive statements" from all clinicians supporting the "obvious use case" for EsoGuard, the analyst tells investors in a research note.

Ascendiant

Buy

maintain

2025-06-06

Reason

Ascendiant

Price Target

2025-06-06

maintain

Buy

Reason

Ascendiant raised the firm's price target on Lucid Diagnostics to $7.75 from $7.50 and keeps a Buy rating on the shares following the Q1 report. The firm says expected high growth in 2025 should drive the stock "much higher."

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$7 → $7.5

2025-04-21

Reason

Ascendiant Capital

Edward Woo

Price Target

$7 → $7.5

2025-04-21

Maintains

Strong Buy

Reason

Ascendiant raised the firm's price target on Lucid Diagnostics to $7.50 from $7 and keeps a Buy rating on the shares following the Q4 report. Lucid's devices still have long commercialization and growth challenges ahead, but the "billion dollars market potential presents high rewards for the risks," the analyst tells investors in a research note. The firm says the company's expected high growth in 2025 should drive the stock "much higher."

Needham

Mike Matson

Strong Buy

Reiterates

2025-04-11

Reason

Needham

Mike Matson

Price Target

2025-04-11

Reiterates

Strong Buy

Reason

Cantor Fitzgerald

Ross Osborn

Buy

Reiterates

2025-03-26

Reason

Cantor Fitzgerald

Ross Osborn

Price Target

2025-03-26

Reiterates

Buy

Reason

Valuation Metrics

The current forward P/E ratio for Lucid Diagnostics Inc (LUCD.O) is -3.09, compared to its 5-year average forward P/E of -2.09. For a more detailed relative valuation and DCF analysis to assess Lucid Diagnostics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.09

Current PE

-3.09

Overvalued PE

-0.14

Undervalued PE

-4.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.67

Current EV/EBITDA

-4.45

Overvalued EV/EBITDA

-0.08

Undervalued EV/EBITDA

-5.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

26.44

Current PS

19.02

Overvalued PS

71.63

Undervalued PS

-18.74

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

LUCD News & Events

Events Timeline

No data

News

8.5

2025-12-30PRnewswire

PAVmed Executes 1-for-30 Reverse Stock Split to Maintain Nasdaq Listing

8.5

2025-12-30Newsfilter

PAVmed Executes 1-for-30 Reverse Stock Split to Maintain Nasdaq Listing

3.5

2025-12-09Newsfilter

Lucid Diagnostics Reports 95% Success Rate in 11,991 EsoGuard Tests for Esophageal Cancer Screening

People Also Watch

Frequently Asked Questions

What is Lucid Diagnostics Inc (LUCD) stock price today?

The current price of LUCD is 1.18 USD — it has decreased -4.07 % in the last trading day.

What is Lucid Diagnostics Inc (LUCD)'s business?

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.

What is the price predicton of LUCD Stock?

What is Lucid Diagnostics Inc (LUCD)'s revenue for the last quarter?

Lucid Diagnostics Inc revenue for the last quarter amounts to 1.21M USD, increased 3.33 % YoY.

What is Lucid Diagnostics Inc (LUCD)'s earnings per share (EPS) for the last quarter?

Lucid Diagnostics Inc. EPS for the last quarter amounts to -0.10 USD, decreased -60.00 % YoY.

What changes have occurred in the market's expectations for Lucid Diagnostics Inc (LUCD)'s fundamentals?

How many employees does Lucid Diagnostics Inc (LUCD). have?

Lucid Diagnostics Inc (LUCD) has 72 emplpoyees as of January 10 2026.

What is Lucid Diagnostics Inc (LUCD) market cap?

Today LUCD has the market capitalization of 154.70M USD.